

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 November 2018 (22.11.2018)



(10) International Publication Number
WO 2018/213751 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 16/00 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2018/033466

(22) International Filing Date:

18 May 2018 (18.05.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/508,702 19 May 2017 (19.05.2017) US

(71) Applicant: LUNELLA BIOTECH, INC. [CA/CA]; 145
Richmond Road, Ottawa, Ontario K1Z 1A1 (CA).

(72) Inventors; and

(71) Applicants: LISANTI, Michael P. [US/US]; 8115 Maple
Lawn Boulevard, #250 (324), Fulton, Maryland 20759

(US). SOTGIA, Federica [US/US]; 8115 Maple Lawn
Boulevard, #350 (324), Fulton, Maryland 20759 (US).

(74) Agent: BRADY, Joshua B.; Nixon & Vanderhye P.C., 901
N. Glebe Road, 11th Floor, Arlington, Virginia 22203 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: ANTIMITOSCINS: TARGETED INHIBITORS OF MITOCHONDRIAL BIOGENESIS FOR ERADICATING CANCER
STEM CELLS

FIG. 1A




FIG. 1B




FIG. 1C





FIG. 1D



(57) Abstract: Antibiotics having intrinsic anti-mitochondrial properties may be chemically modified to target the antibiotics to mitochondria, and the resulting "antimitoscins" may have enhanced anti-cancer properties, among other advantageous properties. Also described are methods for identifying antimitoscins, methods of using antimitoscins to target cancer stem cells, and pharmaceutical compositions for treating cancer containing one or more antimitoscins as the active ingredient. Specific antimitoscins compounds and groups of antimitoscins are also disclosed.

[Continued on next page]

WO 2018/213751 A1

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*